Ignite Creation Date:
2024-05-06 @ 8:12 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06291337
Status:
COMPLETED
Last Update Posted:
2024-03-04
First Post:
2024-02-15
Brief Title:
Ibuprofen Inhibits Human Sweet Taste
Sponsor:
Rutgers The State University of New Jersey
Organization:
Rutgers The State University of New Jersey
Study Overview
Official Title:
Ibuprofen a Phenylpropanoic Acid Nonsteroidal Anti-inflammatory Drug Inhibits Human Sweet Taste and Glucose Detection
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The sweet taste receptor TAS1R2-TAS1R3 is expressed both orally where it signals sweet taste and extraorally in the intestine and pancreas where it may affect glucose absorption and metabolism Recently ibuprofen and naproxen have been identified to inhibit human T1R3 when heterologously expressed in cells In the present study the initial objective was to determine if ibuprofen and naproxen inhibit interactions of sugars with human sweet taste receptor under normal physiological conditions Ten healthy participants were asked to rate sweetness intensity for a range of sweet stimuli sucrose fructose sucralose after a prerinse of ibuprofen naproxen or water Both ibuprofen and naproxen inhibited sweet taste intensity in a dose-dependent manner In association studies ibuprofen use has been linked to preserved metabolic function as its use is correlated with lower rates of Alzheimers disease diabetes and colon cancer Here the investigators present a potential novel pathway for systemic ibuprofen to impact these metabolic diseases
Detailed Description:
The sweet taste receptor TAS1R2-TAS1R3 is expressed both orally where it signals sweet taste and extraorally in the intestine and pancreas where it may affect glucose absorption and metabolism Lactisole is a well characterized negative allosteric modulator of the transmembrane domain of T1R3 Lactisole binds with a phenylpropionic acid moiety More recently ibuprofen and naproxen which are similar to lactisole in structure have been identified to inhibit human T1R3 when heterologously expressed in cells In the present study the initial objective was to determine if ibuprofen and naproxen inhibit interactions of sugars with human sweet taste receptor under normal physiological conditions Ten healthy participants were asked to rate sweetness intensity for a range of sweet stimuli sucrose fructose sucralose after a prerinse of ibuprofen naproxen or water Both ibuprofen and naproxen inhibited sweet taste intensity in a dose-dependent manner The experiment was repeated in vitro with TAS1R2-TAS1R3 expressing human cells with ibuprofen reducing signaling of sucrose and sucralose To explore ibuprofens potential connection with glucose signaling and metabolism the investigators next tested whether prerinses of lower concentrations of ibuprofen including a typical peak plasma concentrations 018 mM 057 mM and 57 mM would affect sweet taste intensity ratings of lower levels of glucose Ibuprofen inhibited glucose sweetness in a dose dependent manner Finally the investigators tested whether prerinses of 012 mM and 024 mM ibuprofen resulting from ingestion of two or three 200 mg pills respectively affects detection thresholds of glucose which are concentrations nearing post-prandial plasma glucose levels Detection thresholds were significantly higher after rinsing with 024 mM ibuprofen compared to water rinses p001 n12 In association studies ibuprofen use has been linked to preserved metabolic function as its use is correlated with lower rates of Alzheimers disease diabetes and colon cancer Here the investigators present a potential novel pathway for systemic ibuprofen to impact these metabolic diseases
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 10-204Mc | OTHER | Rutgers IRB | None |